You are receiving this message since your browser does not support Java Script or you have Java Scripts disabled. The following disclaimer is provided as an alternative to the information that would normally be seen on your monitor when you click on a link to a non-federal site.

"You are now leaving the NIDDK website. The NIDDK is not responsible for the content of web pages found on this linked website. Links to nonfederal organizations are provided solely as a service to our users. These links do not indicate an endorsement of these organizations by NIDDK or the federal government."

Opportunities for Industry

Please visit the following links for more information on industry participation in the special type 1 diabetes funding program:

  • TrialNet: a network of clinical centers, investigators, and core support facilities in the U.S. and Canada that supports the development and implementation of clinical trials of agents to slow the progression of type 1 diabetes in new-onset patients and to prevent type 1 diabetes in those at-risk of developing the disease.
  • Immune Tolerance Network: an international consortium that evaluates promising tolerogenic treatment regimens in four clinical areas: islet transplantation, kidney transplantation, autoimmune diseases, and asthma and allergy diseases.
  • DirecNet: The mission of DirecNet is to investigate the potential use of glucose monitoring technology and its impact on the management of type 1 diabetes in children.
  • Diabetic Retinopathy Clinical Research Network (DRCR.net): The mission of DRCR.net is to facilitate the conduct of multi-center clinical research of diabetic retinopathy, diabetic macular edema, and associated conditions.
  • Trans-Institute Angiogenesis Research Program (TARP): This trans-NIH program is encouraging and facilitating the study of the underlying mechanisms controlling blood vessel growth and development.
  • Non-Human Primate Transplantation Tolerance Cooperative Study Group (NHPCSG): The NHPCSG, a multi-institution consortium, was established to evaluate the safety and efficacy of novel donor-specific, tolerance induction therapies in non-human primate (NHP) models of kidney and islet transplantation. The program also supports research into the immunological mechanisms of tolerance induction and development of surrogate markers for the induction, maintenance, and loss of tolerance.
  • Juvenile Diabetes Research Foundation International (JDRF) industry funding opportunities: please visit http://www.jdrf.org/index.cfm@P1page_id=103238
  • NIH Resources for SBIR/STTR
    NIH SBIR/STTR Program | NIDDK SBIR/STTR Program and Staff Contacts




Last Updated: 3/22/2006

General Inquiries may be addressed to:
Office of Communications and Public Liaison
NIDDK, NIH
Building 31, Rm 9A06
31 Center Drive, MSC 2560
Bethesda, MD 20892-2560 USA
For information about NIDDK programs: 301.496.3583